Roche has agreed to pay Rona Therapeutics up to $100 million in upfront and short-term milestone payments to secure rights to an investigational RNA interference (RNAi) therapy targeting ALK7, adding another potential approach to its obesity portfolio.
The agreement places Roche alongside Novo Nordisk, GSK, Alnylam and Arrowhead Pharmaceuticals among companies exploring this emerging therapeutic target.
ALK7, a protein encoded by the ACVR1C gene, has attracted interest because of its role in fat metabolism and its advantageous expression in adipose tissue. Human genetic research has associated certain ALK7 variants with lower waist-to-hip ratios, an indicator of abdominal fat accumulation. Studies in mice have also found that disrupting ALK7 signaling can protect against obesity, encouraging pharmaceutical companies to investigate the pathway as a potential treatment target.
Under the agreement announced Tuesday, Roche will receive an exclusive license to Rona’s ALK7-targeting RNAi candidate. Beyond the initial payments, Rona could receive over $1 billion in additional milestones, along with royalties that increase according to sales tiers.
The companies have not revealed the candidate’s development code or its current stage of research. However, the program uses Rona’s platform for delivering RNAi medicines to tissues outside the liver, potentially enabling the treatment to reach targets in adipose tissue.
Rona’s publicly disclosed pipeline includes two preclinical obesity programs directed at undisclosed targets. None of its other assets with publicly identified targets is known to act on ALK7.
Rona CEO Stella Shi said the collaboration reflects the need for treatments capable of delivering weight loss that is both higher quality and more sustainable. She described ALK7 as an attractive target for obesity and metabolic disorders because of its potential to influence the underlying biology of fat tissue.
Researchers believe that inhibiting this pathway could help reduce fat accumulation while retaining lean body mass. ALK7-targeting treatments might also work independently or alongside incretin-based medicines, including GLP-1 receptor agonists.
Early clinical findings from other companies have begun to support interest in the approach. Arrowhead reported in January that a single administration of its ALK7-targeting candidate produced an over 14% reduction in visceral fat relative to placebo after eight weeks.
Alnylam, meanwhile, has scheduled Phase 1 findings for its own ALK7 program for the second half of 2026, following the start of a clinical trial in March.
GSK entered the field in May, paying China’s SiranBio $55 million for a Phase 1-stage candidate targeting the same pathway. Novo Nordisk also disclosed multiple ALK7 programs at its investor day last month. The Danish pharmaceutical company said its most advanced candidate was expected to enter clinical testing during the year.
Roche’s latest agreement supports its ambition to become one of the three leading companies in obesity treatment. The Swiss drugmaker has pursued that goal through acquisitions and licensing arrangements, including its $2.7 billion purchase of Carmot Therapeutics and agreements with Zealand Pharma and Hanmi Pharmaceutical.
Its progress in obesity has not been without obstacles, however. Roche has discontinued one candidate after an interim analysis failed to support continued development, while questions remain about the prospects of enicepatide and petrelintide.
Roche is strengthening its position in the competitive obesity-treatment market as pharmaceutical companies search for new approaches to weight management and metabolic health. The reported deal with Rona, alongside interest in ALK7 as a potential obesity target, highlights the industry’s growing focus on next-generation medicines that could complement existing GLP-1 therapies.
Obesity drug development has become a major area of investment as researchers explore treatments that can deliver meaningful weight reduction, improve metabolic health, and potentially offer alternatives for patients who cannot tolerate or adequately respond to existing medicines. For Roche, expanding its pipeline through partnerships and emerging biological targets could create new opportunities in a market experiencing rapid scientific and commercial change.
The agreement and the ALK7 research effort also reflect a wider pharmaceutical trend: companies are increasingly combining external innovation with internal research to diversify their development programs and strengthen their long-term competitive positions.
Roche is entering an increasingly competitive field as other pharmaceutical and biotechnology companies investigate ALK7 for obesity and metabolic diseases.
Companies including Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, GSK, and Novo Nordisk have pursued programs or research initiatives involving this target. Their approaches and development stages vary, making it important to compare the available evidence rather than assume that all candidates are equally advanced.
Competition could encourage improvements in drug delivery, dosing schedules, treatment durability, and the ability to target specific fat depots. It may also help researchers determine whether ALK7 inhibition offers meaningful benefits beyond existing weight-management medicines.
For Roche, the challenge will be translating the biological rationale behind the licensed candidate into clinical evidence that demonstrates safety, efficacy, and a meaningful advantage for patients.
How the Deal Fits Roche’s Broader Obesity Strategy
Roche has been expanding its presence in obesity treatment through acquisitions, research programs, and partnerships. Its existing activities include work with Carmot Therapeutics and a collaboration with Zealand Pharma on obesity treatments.
The Rona agreement adds a distinct research approach to this portfolio. Rather than relying exclusively on incretin-based medicines, Roche is also exploring biological pathways that may influence fat metabolism through different mechanisms.
A diversified pipeline can help a pharmaceutical company address different patient needs, particularly when a single treatment mechanism does not provide suitable results for everyone. Nevertheless, a broader portfolio does not guarantee commercial success, and each investigational medicine must establish its value through clinical development.
Potential Benefits for Patients and Future Research
If future studies demonstrate that ALK7 inhibition is safe and effective, this approach could contribute to a wider range of treatment options for people living with obesity and associated metabolic conditions.
Researchers are particularly interested in whether targeting adipose tissue could reduce harmful fat accumulation while preserving lean body mass. Such an outcome could be valuable, but it has not yet been established for Roche’s licensed candidate.
